类人慢性粒细胞性白血病小鼠模型的建立

 目的：为了进一步阐明慢性粒细胞性白血病(chronic myeloid leukemia,CML) 的发病机制、寻找新的治疗靶点,有必要建立CML动物模型。方法：首先改进逆转录病毒包装技术,在相同实验条件下,改变以下条件之一,如质粒的质量、包装细胞的状态、转染当天包装细胞的密度等,进行病毒滴度的测定,优化实验条件后进行后续实验。实验组为BCR/ABL(含BCR/ABL融合基因的逆转录病毒载体)组小鼠。供体小鼠经5-氟尿嘧啶（5-FU）预处理后,骨髓细胞经p210 BCR/ABL逆转录病毒上清感染,感染的骨髓细胞经尾静脉注射给经致死剂量X光照射的受体小鼠。观察移植后BCR/ABL组小鼠的活动情况、发病鼠外周血和骨髓的细胞形态、肝脾病理改变等。同时观察MigR1(逆转录病毒空载体)组小鼠。结果：通过提高质粒的质量、改善包装细胞的状态、优化转染当天包装细胞的密度等,提高了病毒的滴度,用于小鼠移植模型实验。BCR/ABL组小鼠均于移植后19～25 d发病死亡。发病时外周血及骨髓均见中晚幼及成熟粒细胞大量增生,肝脾肿大伴正常结构破坏及大量粒细胞浸润。MigR1组小鼠均无发病。结论: 通过改进逆转录病毒包装技术,提高包装病毒的滴度,我们在体外将BCR/ABL转入小鼠骨髓细胞并移植入受体小鼠,成功建立了类人CML小鼠模型。

Establishment of a human chronic myeloid leukemia-like mouse model

AIM：To establish a new model of chronic myeloid leukemia (CML) for further studying the pathogenesis mechanisms and discovering new therapeutic targets of this disease. METHODS：The retroviral packaging technique was improved by increasing retroviral titer with higher-quality plasmid, better cell state and appropriate cell seeding density for further studying. Donor BALB/c mice were pretreated with 5-fluorouracil (5-FU), and their bone marrow cells were infected with p210 BCR/ABL retroviral supernatant (BCR/ABL group) or empty retroviral vector (MigR1) supernatant (MigR1 group). Infected bone marrow cells were transplanted into lethally irradiated recipient BALB/c mice via tail vein. The activities of the mice were observed after bone marrow transplantation (BMT). The morphology of peripheral blood cells and bone marrow cells, and the pathological changes of the liver and spleen in dying mice were also determined. RESULTS：Retroviral packaging efficiency was improved by optimizing the experimental conditions with higher-quality plasmid, better cell state and appropriate cell seeding density. All mice in BCR/ABL group died at 19 to 25 d after BMT. Their myelocytes, metamyelocytes and mature granulocytes in peripheral blood and bone marrow were abundant. Hepatosplenomegaly and granulocyte infiltration in the liver and spleen were also observed. All mice in MigR1 group were normal. CONCLUSION: We have successfully set up a mouse model of CML by increasing retroviral titer with improved retroviral packaging technique, transfecting BCR/ABL into mouse bone marrow cells in vitro and transplanting the cells to the recipients of the same lineage.